Loading...
XSHG
600420
Market cap2.09bUSD
Jul 25, Last price  
11.16CNY
1D
-0.89%
1Q
8.14%
Jan 2017
-32.61%
IPO
391.63%
Name

Shanghai Shyndec Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
13.81
P/S
1.37
EPS
0.81
Div Yield, %
1.79%
Shrs. gr., 5y
3.10%
Rev. gr., 5y
-2.16%
Revenues
10.94b
-8.33%
502,746,161545,870,580624,322,933687,231,9331,164,233,7281,422,963,6451,702,623,2752,006,892,2342,349,747,9942,748,835,6682,682,244,6909,125,774,7738,517,753,72611,320,781,39312,199,106,72512,556,281,59513,944,948,27012,959,320,53311,931,810,34310,937,525,114
Net income
1.08b
+56.62%
58,686,12150,497,72894,029,95853,914,13789,052,252108,111,439120,032,511115,944,722132,787,532189,991,042221,052,732476,933,718515,802,593705,521,698928,467,067900,046,866821,145,853867,484,979691,880,4951,083,622,881
CFO
2.26b
+31.13%
57,898,13273,595,32782,308,03658,044,42597,434,742115,105,986136,123,080193,411,432207,496,007258,514,766226,646,450838,576,8382,314,541,6561,669,140,5751,270,137,2121,560,179,0111,679,662,3932,855,633,1051,720,373,7882,255,980,695
Dividend
Sep 20, 20240.1 CNY/sh

Profile

Shanghai Shyndec Pharmaceutical Co., Ltd. manufactures drug preparation products in China and internationally. It focuses on anti-infection, cardiovascular and cerebrovascular, anti-tumor, metabolism, and endocrine areas. The company was founded in 1996 and is based in Shanghai, China.
URL
http://www.shyndec.com/
IPO date
Jun 16, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
10,937,525
-8.33%
11,931,810
-7.93%
12,959,321
-7.07%
Cost of revenue
8,094,742
10,105,252
11,417,539
Unusual Expense (Income)
NOPBT
2,842,783
1,826,559
1,541,782
NOPBT Margin
25.99%
15.31%
11.90%
Operating Taxes
340,974
131,949
116,635
Tax Rate
11.99%
7.22%
7.56%
NOPAT
2,501,808
1,694,610
1,425,147
Net income
1,083,623
56.62%
691,880
-20.24%
867,485
5.64%
Dividends
(189,355)
(102,698)
Dividend yield
1.52%
0.98%
Proceeds from repurchase of equity
1,188,000
BB yield
-11.29%
Debt
Debt current
50,051
45,048
379,373
Long-term debt
95,874
1,146,889
3,092,562
Deferred revenue
113,990
122,802
138,006
Other long-term liabilities
57,320
518
571
Net debt
(6,066,016)
(5,218,145)
(3,116,755)
Cash flow
Cash from operating activities
2,255,981
1,720,374
2,855,633
CAPEX
(357,194)
Cash from investing activities
(1,389,079)
Cash from financing activities
(1,093,390)
FCF
2,771,573
2,551,531
1,715,376
Balance
Cash
6,211,941
5,972,611
6,148,196
Long term investments
2
437,471
440,493
Excess cash
5,665,065
5,813,492
5,940,723
Stockholders' equity
9,677,856
8,697,400
8,574,837
Invested Capital
9,926,198
9,782,014
9,603,491
ROIC
25.39%
17.48%
14.61%
ROCE
18.15%
11.70%
9.84%
EV
Common stock shares outstanding
1,341,173
1,273,478
1,156,373
Price
11.94
21.96%
9.79
7.58%
9.10
-12.25%
Market cap
16,013,602
28.44%
12,467,348
18.48%
10,522,993
-13.84%
EV
12,065,626
9,199,055
9,253,515
EBITDA
3,615,101
2,645,444
2,384,270
EV/EBITDA
3.34
3.48
3.88
Interest
36,888
57,884
107,310
Interest/NOPBT
1.30%
3.17%
6.96%